The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs).Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively).Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Six retrospective cohort studies on individuals with biopsy-proven MASLD showed that NFS and FIB-4 predict the occurrence of liver-related events (AUROCs from 0.72 to 0.86) and overall mortality (AUROCs from 0.67 to 0.82), 176,177 with a similar or lower accuracy compared to histology.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Gedaly, 2012, Rising incidence of nonalcoholic steatoheptitis among patients transplanted for hepatocellular carcinoma in the United States, Hepatology, 56, 40A
Cited by
Sorted by citations
Items 201–300 of 501
Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population
Liu, X., Zhang, H. T., Fang, C., Li, L., Lai, Z.-Q., Liang, N., Zhang, X., Wu, M., Yin, X., Zhang, H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.035371 · Cited by 31
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
Perazzo, H., Munteanu, M., Ngo, Y., Lebray, P., Seurat, N., Rutka, F., Couteau, M., Jacqueminet, S., Giral, P., Monneret, D., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12946 · Cited by 31
Jaruvongvanich, V., Wijarnpreecha, K., & Ungprasert, P. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.03.010 · Cited by 31
Kamada, Y., Nakamura, T., Isobe, S., Hosono, K., Suama, Y., Ohtakaki, Y., Nauchi, A., Yasuda, N., Mitsuta, S., Miura, K., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01932-1 · Cited by 31
Takahashi, K., Kawanaka, M., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Morishita, A., Munekage, K., et al. (2023) · Nutrients · doi:10.3390/nu15092014 · Cited by 33
Seko, Y., Sumida, Y., Tanaka, S., Taketani, H., Kanemasa, K., Ishiba, H., Okajima, A., Nishimura, T., Yamaguchi, K., Moriguchi, M., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12407 · Cited by 30
An overview of the genetics, mechanisms and management of NAFLD and ALD
Rowell, R., & Anstee, Q. M. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s77 · Cited by 32
Targeting Hepatic Fibrosis in Autoimmune Hepatitis
Montaño‐Loza, A. J., Thandassery, R. B., & Czaja, A. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4254-7 · Cited by 30
Braude, M. R., Roberts, S. K., Majeed, A., Lubel, J. S., Prompen, J., Dev, A. T., Sievert, W., Bloom, S., Gow, P. J., & Kemp, W. W. (2022) · Liver International · doi:10.1111/liv.15415 · Cited by 29
Nonalcoholic Fatty Liver Disease
Seth, A., & Balakrishnan, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48662-8_5
Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake
Aboona, M. B., Danpanichkul, P., Chen, V. L., Rangan, P., Kim, D., Alkhouri, N., Fallon, M. B., Noureddin, M., Arab, J. P., & Wijarnpreecha, K. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16726 · Cited by 29
Lee, J. I., Yu, J. H., Anh, S. G., Lee, H. W., Jeong, J., & Lee, K. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0370 · Cited by 29
Männistö, V., Salomaa, V. V., Färkkilä, M. A., Jula, A., Männistö, S., Erlund, I., Sundvall, J., Lundqvist, A., Perola, M., & Åberg, F. O. (2021) · Liver International · doi:10.1111/liv.15004 · Cited by 29
Vincentis, A. D., Costanzo, L., Gentilucci, U. V., Picardi, A., Bandinelli, S., Ferrucci, L., Incalzi, R. A., & Pedone, C. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.01.017 · Cited by 28
Liu, Y., Zhang, D., Liu, G., Chen, Q., & Lu, Z. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.04.051 · Cited by 28
The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
Perazzo, H., Poynard, T., & Dufour, J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.014 · Cited by 28
Forsgren, M. F., Nasr, P., Karlsson, M., Dahlström, N., Norén, B., Ignatova, S., Sinkus, R., Cedersund, G., Leinhard, O. D., Ekstedt, M., et al. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1786599 · Cited by 27
Non-alcoholic fatty liver disease
Li, W., & Alazawi, W. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0696 · Cited by 27
Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?
Fielding, C. M., & Angulo, P. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0227-5 · Cited by 27
Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease
Jayakumar, S., Harrison, S. A., & Loomba, R. S. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0296-8 · Cited by 26
Lombardi, R. (2017) · Annals of Gastroenterology · doi:10.20524/aog.2017.0141 · Cited by 26
Nogami, A., Yoneda, M., Kobayashi, T., Kessoku, T., Honda, Y., Ogawa, Y., Suzuki, K., Tomeno, W., Imajo, K., Kirikoshi, H., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13349 · Cited by 26
Wang, B., Li, M., Zhao, Z., Wang, S., Lu, J., Chen, Y., Xu, M., Wang, W., Ning, G., Bi, Y., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa112 · Cited by 26
Roman, J. H., & Siddiqui, M. S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.127 · Cited by 26
Kirnake, V., Arora, A., Sharma, P., Goyal, M. B., Chawlani, R., Toshniwal, J., & Kumar, A. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0879-0 · Cited by 25
Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
Goossens, N., Bellentani, S., Cerny, A., Dufour, J., Jornayvaz, F., Mertens, J., Moriggia, A., Muellhaupt, B., Negro, F., Razavi, H., et al. (2019) · Swiss medical weekly · doi:10.4414/smw.2019.20152 · Cited by 22
Zhang, Z., Zhang, W., Liu, Z., Ou, J., Sun, Y., Zhang, L., & Ji, G. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.019 · Cited by 24
Non-alcoholic fatty liver disease–a chronic disease of the 21st century
Metrakos, P. P., & Tommy, N. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160153 · Cited by 24
FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients
Kawata, N., Takahashi, H., Iwane, S., Inoue, K., Kojima, M., Kohno, M., Tanaka, K., Mori, H., Isoda, H., Oeda, S., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00453-7 · Cited by 24
Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer
Song, D., Hu, Y., Diao, B., Miao, R., Zhang, B., Cai, Y., Zeng, H., Zhang, Y., & Hu, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08538-5 · Cited by 24
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Noureddin, N., Copur‐Dahi, N., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17752 · Cited by 25
Sharma, N., Sircar, A., Anders, H., & Gaikwad, A. B. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1745851 · Cited by 25
Chun, H. S., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, Y., Kim, Y. D., & Kim, S. U. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15387 · Cited by 23
Utility of Multiparametric CT for Identification of High-Risk NAFLD
Lubner, M. G., Graffy, P. M., Said, A., Watson, R. F., Zea, R. D., Malecki, K. M., & Pickhardt, P. J. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.20.22842 · Cited by 23
Identification of high-risk subjects in nonalcoholic fatty liver disease
Stern, C., & Castéra, L. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0431 · Cited by 24
Nonalcoholic Fatty Liver Disease
Gawrieh, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_14 · Cited by 25
Wong, R. J., Tran, T. T., Kaufman, H. W., Niles, J. K., & Gish, R. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220612 · Cited by 23
Cao, Y., Zhang, M., Zhang, H., Jin, J., Liu, H., Zhang, Y., Guo, Y., Wu, N., Zhu, C., Xu, R., et al. (2021) · Liver International · doi:10.1111/liv.14780 · Cited by 23
Gaia, S., Campion, D., Evangelista, A., Spandre, M., Cosso, L., Brunello, F., Ciccone, G., Bugianesi, E., & Rizzetto, M. (2014) · Liver International · doi:10.1111/liv.12761 · Cited by 23
Hsu, C., Parikh, N. D., Huo, T., & Tapper, E. B. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06763-9 · Cited by 22
NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE.
Boursier, J., Guillaume, M., Bouzbib, C., Lannes, A., Pais, R., Smatti, S., Cariou, B., Bureau, C., Ganne-Carrié, N., Bourlière, M., et al. (2021) · Clinics And Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101769 · Cited by 21
Hydes, T., Brown, E. E., Hamid, A., Bateman, A. C., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.012 · Cited by 22
Metabolic Syndrome After Pediatric Liver Transplantation
Kosola, S. K., Lampela, H., Mäkisalo, H., Lohi, J., Arola, J., Jalanko, H., & Pakarinen, M. P. (2014) · Liver Transplantation · doi:10.1002/lt.23931 · Cited by 22
Non-invasive prediction of forthcoming cirrhosis-related complications
Kang, W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2613 · Cited by 22
Identifying High-Risk NASH Patients: What We Know so Far
Schulz, M., & Tacke, F. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265473 · Cited by 21
Torres, L., Schuch, A., Longo, L., Valentini, B. B., Galvão, G. S., Luchese, E., Pinzon, C., Bartels, R., & Álvares‐da‐Silva, M. R. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100774 · Cited by 21
Practical approach to non‐alcoholic fatty liver disease in patients with diabetes
Tai, F. W. D., Syn, W., & Alazawi, W. (2015) · Diabetic Medicine · doi:10.1111/dme.12725 · Cited by 21
The value of neck circumference (NC) as a predictor of non-alcoholic fatty liver disease (NAFLD)
Hu, Y., Chen, J., Lü, Y., Chen, P., Li, J., Chen, L., Chen, J., Huang, X., Zhang, Y., Bu, S., et al. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.07.001 · Cited by 21
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Stine, J. G., Schreibman, I., Navabi, S., Kang, M., Dahmus, J., Soriano, C., Rivas, G., Hummer, B., Beyer, M., Tressler, H., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100560 · Cited by 19
Higher NAFLD fibrosis score is associated with impaired eGFR.
Hsieh, M., Wu, K.-T., Chen, Y.-Y., Yang, J.-F., Lin, W.-Y., Chang, N., Lin, C.-Y., Huang, C.-K., Wang, C.-L., Chuang, H., et al. (2019) · Journal of the Formosan Medical Association = Taiwan yi zhi · doi:10.1016/j.jfma.2019.07.007 · Cited by 16
Sakane, S., Hikita, H., Shirai, K., Sakamoto, T., Narumi, R., Adachi, J., Kakita, N., Yamada, Y., Toyoda, H., Takahashi, H., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000448 · Cited by 20
Feng, Y., Xu, W., Tang, S., Ye, Z., Fang, P., Abdullah, G., Yang, H., Kong, D., Huang, H., Wang, Y., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111749 · Cited by 20
Machado, M. V., Krüger, L., Jewell, M. L., Michelotti, G. A., Pereira, T. A., Xie, G., Moylan, C. A., & Diehl, A. M. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3871-x · Cited by 20
Kern, B., Feurstein, B., Fritz, J., Fabritius, C., Sucher, R., Graziadei, I. W., Bale, R. J., Tilg, H., Zoller, H., Newsome, P. N., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001270 · Cited by 20
Ünsal, İ. Ö., Çalapkulu, M., Sencar, M. E., Çakal, B., & Özbek, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04361-x · Cited by 21
Screening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 19
Halfon, P., Ansaldi, C., Pénaranda, G., Chiche, L., Dukan, P., Stavris, C., Plauzolles, A., Rétornaz, F., & Bourlière, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254939 · Cited by 19
Wu, Y., Yang, X., Morris, H., Gurka, M. J., Shenkman, E. A., Cusi, K. J., Bril, F., & Donahoo, W. T. (2022) · JMIR Medical Informatics · doi:10.2196/36997 · Cited by 19
Choi, S.-W., Kweon, S., Lee, Y. H., Ryu, S. Y., Nam, H., & Shin, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277729 · Cited by 19
Sanyal, A. J., Muñoz, B., Cusi, K. J., Barritt, A. S., Muthiah, M. D., Mospan, A. R., Reddy, K. R., Firpi-Morell, R. J., Thuluvath, P. J., Bhamidimarri, K. R., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.024 · Cited by 19
Augustín, S., Ahmed, A., Alkhouri, N., Canbay, A. E., Corless, L., Nakajima, A., Okanoue, T., Petta, S., Ratziu, V., Tsochatzis, E. A., et al. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-775 · Cited by 19
Mao, X., Liu, Z., Shi, O., Yu, K., Jiang, Y., Li, J., Zhang, T., & Chen, X. (2020) · Hepatology Research · doi:10.1111/hepr.13570 · Cited by 19
Decraecker, M., Dutartre, D., Hiriart, J., Irlès‐Depé, M., Chermak, F., Foucher, J., & de Lédinghen, V. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16760 · Cited by 19
Yan, C., Zhang, W., Xiao, Y., Sun, Y., Peng, X., & Cai, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376894 · Cited by 18
García‐Compeán, D., Villarreal‐Pérez, J. Z., de la O-Cavazos, M. E., Lavalle-Gonzalez, F. J., Borjas-Almaguer, O. D., del Cueto-Aguilera, Á. N., González, J. A., Treviño‐Garza, C., Huerta-Pérez, L., & Maldonado-Garza, H. J. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.01.003 · Cited by 18
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Kearns, P. K. A., Hayes, P. C., Guha, I. N., Morling, J. R., Glancy, S., Williamson, R. M., Reynolds, R. M., et al. (2020) · Liver International · doi:10.1111/liv.14590 · Cited by 17
Cianci, N., Subhani, M., Hill, T., Khanna, A., Zheng, D., Sheth, A., Crooks, C. J., & Aithal, G. P. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i5.1025 · Cited by 17
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02408-7 · Cited by 17
Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome
Han, M. A. T. (2020) · Life · doi:10.3390/life10090198 · Cited by 17
Pennisi, G., Pipitone, R. M., Enea, M., Vincentis, A. D., Battaglia, S. L., Marco, V. D., Martino, V. D., Spatola, F., Tavaglione, F., Gentilucci, U. V., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1877 · Cited by 17
Bertrais, S., Boursier, J., Ducancelle, A., Oberti, F., Fouchard‐Hubert, I., Moal, V., & Calès, P. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13668 · Cited by 17
Wang, L., Wang, X., Kong, L., Li, Y., Huang, K., Wu, J., Wang, C., Sun, H., Sun, P., Gu, J., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7334 · Cited by 16
Zhang, X., Xin, Y., Yang, Y., Chen, Y., Cao, X., Wang, Y., Fan, Q., Zhou, X., & Li, X. (2022) · International Journal of Hyperthermia · doi:10.1080/02656736.2022.2043457 · Cited by 16
Xia, M., Chen, L., Wu, L., Ma, H., Li, Q., Aleteng, Q., Hu, Y., He, W., Gao, J., Lin, H., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15372 · Cited by 16
Aller, R., Fernández‐Rodríguez, C., Iacono, O. L., Bañares, R., Abad, J., Carrión, J. A., García‐Monzón, C., Caballería, J., Berenguer, M., Rodríguez‐Perálvarez, M., et al. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2018.05.013 · Cited by 16
Festi, D., Schiumerini, R., Marasco, G., Scaioli, E., Pasqui, F., & Colecchia, A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1049155 · Cited by 17
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease
Kwak, M., & Kim, D. (2015) · Current Hepatology Reports · doi:10.1007/s11901-015-0258-6 · Cited by 16
NASH, from diagnosis to treatment: Where do we stand?
Harrison, S. A. (2015) · Hepatology · doi:10.1002/hep.28275 · Cited by 16
Karlas, T., Petroff, D., & Wiegand, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.12.013 · Cited by 16
Song, X., Liu, B., Lei, F., Liu, Y.-M., Zhang, X., Chen, Z., Zhang, P., Zhang, X., She, Z., Cai, J., et al. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s394414 · Cited by 15
Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population
Xiong, S., Yin, S., Deng, W., Zhao, Y., Li, W., Wang, P., Li, Z., Yang, H., Zhou, Y., Yu, S., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003394 · Cited by 16
Predicting liver-related events in NAFLD: A predictive model
Bertot, L. C., Jeffrey, G. P., Wang, Z., Huang, Y., Garas, G., Wallace, M., de Boer, B., George, J., Eslam, M., Phu, A. L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000356 · Cited by 15
Cacciola, I., Filomia, R., Alibrandi, A., Franzè, M. S., Caccamo, G., Maimone, S., Saitta, C., Saffioti, F., Squadrito, G., & Raimondo, G. (2017) · Liver International · doi:10.1111/liv.13649 · Cited by 15
Zhang, J., Luo, Y., Li, C., Liu, J., Xiang, H., & Wen, T. (2019) · BioScience Trends · doi:10.5582/bst.2019.01212 · Cited by 15
Choi, J. M., Park, H. E., Han, Y. M., Lee, J., Lee, H., Chung, S. J., Lim, S. H., Yim, J. Y., & Chung, G. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.844954 · Cited by 15
Brandman, D., Boyle, M., McPherson, S., Natta, M. L. V., Sanyal, A. J., Kowdley, K. V., Neuschwander‐Tetri, B. A., Chalasani, N., Abdelmalek, M. F., Terrault, N. A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16874 · Cited by 16
Impact of liver fibrosis score on the incidence of stroke: A cohort study
Xiong, S., Yin, S., Deng, W., Zhao, Y., Li, W., Wang, P., Li, Z., Yang, H., Zhou, Y., Yu, S., et al. (2022) · Liver International · doi:10.1111/liv.15359 · Cited by 15
Nassif, A. T., Nagano, T. A., Okayama, S., Nassif, L. S., Filho, A. B., & Sampaio-Neto, J. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2284-z · Cited by 15
Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?
Hatton, G. B., Alterio, T., Nobili, V., & Mann, J. P. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1512853 · Cited by 15
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Gallacher, J., & McPherson, S. (2018) · European Medical Journal · doi:10.33590/emj/10314271 · Cited by 15
Sung, K., Johnston, M. P., Lee, M. Y., & Byrne, C. D. (2020) · Liver International · doi:10.1111/liv.14416 · Cited by 15
Kosick, H. M.-K., McIntosh, C., Bera, C., Fakhriyehasl, M., Shengir, M., Adeyi, O. A., Amiri, L., Sebastiani, G., Jhaveri, K. S., & Patel, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-09288-1 · Cited by 15
Fox, R. K., Chu, J. N., Goldman, M. L., Islam, K. B., & Brandman, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000024 · Cited by 14
El-Eshmawy, M. M. (2023) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000228 · Cited by 17
Okamura, Y., Ashida, R., Yamamoto, Y., Ito, T., Sugiura, T., Bekku, E., Aramaki, T., & Uesaka, K. (2016) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-016-1389-0 · Cited by 14
Serum levels of endotrophin are associated with nonalcoholic steatohepatitis
Hagström, H., Bu, D., Nasr, P., Ekstedt, M., Hegmar, H., Kechagias, S., Zhang, N., An, Z., Stal, P. I., & Scherer, P. E. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1879249 · Cited by 14
Chen, L., Zhang, J., Lu, T., Cai, J., Zheng, J., Yao, J., Yi, S., Li, H., Chen, G., Zhao, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6180 · Cited by 14
Biochemical assessment of metabolic associated fatty liver disease
Guerra-Ruiz, A. R., Casals, G., Iruzubieta, P., Lalana, M., Leis, A., López, R. M., Crespo, J., & Morales‐Ruiz, M. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2021-0009 · Cited by 14
Pennisi, G., Pipitone, R. M., Cabibi, D., Enea, M., Romero‐Gómez, M., Viganò, M., Bugianesi, E., Wong, V. W., Fracanzani, A. L., Sebastiani, G., et al. (2022) · Liver International · doi:10.1111/liv.15232 · Cited by 13
Metadata
- Authors
- Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Turin (IT)
- National University Hospital of Iceland (IS)
- Siriraj Hospital (TH)
- Gartnavel General Hospital (GB)
- Newcastle University (GB)
- The University of Sydney (AU)
- Corresponding author
- Angulo, Paul
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 145
- Issue
- 4
- Pages
- 782-789.e4
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3931256
- OpenAlex
- W2129639561
- Cited by
- 502
- References
- 32
- Citations by year
- 2026: 7 · 2025: 29 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 60 · 2020: 49 · 2019: 40 · 2018: 39 · 2017: 35 · 2016: 36 · 2015: 49 · 2014: 45 · 2013: 4
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (R01 DK82426)
- Seventh Framework Programme (HEALTH-F2-2009-241762)
- National Health and Medical Research Council (1049857, 632630)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, NAFLD fibrosis score, FIB-4, BARD score, liver complications, mortality, liver transplantation, disease progression, prognosis, liver fibrosis, risk stratification, prognostic accuracy
- MeSH terms
- Adult, Fatty Liver, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Cohort Studies, Kaplan-Meier Estimate, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
